Oxurion Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Oxurion hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-€0.0015
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Feb 01

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von OXUR in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von OXUR gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Oxurion Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von OXUR im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (OXUR)	n/a
Untere 25 % des Marktes (BE)	2.1%
Markt Top 25 % (BE)	7.1%
Branchendurchschnitt (Biotechs)	1.8%
Analystenprognose in 3 Jahren (OXUR)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von OXUR im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von OXUR im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von OXUR, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da OXUR keine Ausschüttungen gemeldet hat.

Oxurion Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)

New minor risk - Financial data availability

Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024

Oxurion NV, Annual General Meeting, May 07, 2024

Oxurion Announces CEO Changes

Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)

Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023

Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema

High number of new and inexperienced directors

Less than half of directors are independent

Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

Oxurion NV Announces Interim Analysis for KALAHARI Trial

Price target decreased to €1.25

Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Price target increased to €10.00

Oxurion NV, Annual General Meeting, May 02, 2023

Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Oxurion NV Announces New Data on THR-149 Phase 2 Clinical Trial in DME At the Angiogenesis, Exudation, and Degeneration 2022 Conference

Oxurion Provides Update on Clinical Pipeline Progress

Oxurion NV announced that it has received €10 million in funding from Pontifax Ltd., Kreos Capital Management (UK) Limited

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Full year 2020 earnings released

Oxurion NV announced that it expects to receive €30 million in funding from Negma Group Ltd.

Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)

Oxurion NV to Report Fiscal Year 2020 Final Results on Apr 05, 2021

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer

How Is Oxurion's (EBR:OXUR) CEO Compensated?

New 90-day high: €2.90

Oxurion NV to Report Fiscal Year 2021 Results on Mar 17, 2022

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Oxurion NV Announces Executive Changes

Baron Philippe Vlerick, Non-Executive member of the Board of ThromboGenics NV acquired 3.6% stake in ThromboGenics NV (ENXTBR:THR).

New 90-day low: €2.45

Oxurion NV(ENXTBR:OXUR) dropped from S&P Global BMI Index

First half earnings released

Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)

New 90-day low - €2.57

Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen